drugset
drugset / Trial / NCT06050226

A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT06050226 ↗

Phase 2 Completed 34 enrolled Wuhan Createrna Science and Technology Co., Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the efficacy of MY008211A in adult patients with PNH , showing signs of active hemolysis, in China.

Timeline

Start
2023-07-06
Primary completion
2024-04-30
Completion
2024-11-28

Drugs

EvaluationDrugModalityDoseRoute
Subject MY008211A Unknown — Oral

Indications

paroxysmal nocturnal hemoglobinuria